Clinical Trials Browser

Phase 2 × Hodgkin Disease × Immune Checkpoint Inhibitors × Clear all

NCT05137886 2021-12-17

PD-1 Inhibitor Combined With Decitabine Followed by ASCT as Second-line Therapy for Relapsed or Refractory Classic Hodgkin's Lymphoma

Phase 2 Unknown

Hodgkin Disease, Recurrence